Header Logo

Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.

Szyd?owski M, Garbicz F, Jab?o?ska E, Górniak P, Komar D, Pyrzy?ska B, Bojarczuk K, Prochorec-Sobieszek M, Szumera-Cie?kiewicz A, Rymkiewicz G, Cybulska M, Statkiewicz M, Gajewska M, Mikula M, Go?as A, Domaga?a J, Winiarska M, Graczyk-Jarzynka A, Bia?opiotrowicz E, Polak A, Barankiewicz J, Pu?a B, Pawlak M, Nowis D, Golab J, Tomirotti AM, Brzózka K, Pacheco-Blanco M, Kupcova K, Green MR, Havranek O, Chapuy B, Juszczy?ski P. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Res. 2021 12 01; 81(23):6029-6043.

View in: PubMed